FTC Final Order with Baxter International and Claris Lifesciences Preserves U.S. Competition for the Injectable Drugs Intravenous Fluconazole and Intravenous Milrinone
Date
Following a public comment period, the Federal Trade Commission has approved a final order designed to remedy the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of...